EXORPHIA Unveils Groundbreaking MSC-EV Research at Japan Embryology Conference

EXORPHIA, a Tokyo-based biotechnology company, is preparing to present its latest research at the 43rd annual meeting of the Japan Society for Reproductive Medicine, which will take place on August 28-29, 2025, at the Nagoya Marriott Associa Hotel. The event is recognized as one of Japan's most prestigious conferences focusing on reproductive medicine and studies related to embryology and implantation.

About the Presentation

The presentation titled "Qualitative Improvement Effects of MSC-EV on Aging Mouse Embryos: A Promising Approach Toward Pregnancy" will delve into the application of extracellular vesicles (EV) derived from mesenchymal stem cells (MSC) obtained from umbilical cords in embryo culture. Through comprehensive research, EXORPHIA has confirmed substantial benefits of MSC-EV, which include increased blastocyst rates, shortened time to reach the blastocyst stage, and overall improvement in embryo quality. Notably, improvement effects have been observed even in aging mouse embryos equivalent to those in the late 40s of human age, raising exciting prospects for future clinical applications as additives in IVF culture media.

Presentation Details

- Event: 43rd Annual Meeting of the Japan Society for Reproductive Medicine
- Date & Time: August 28, 2025, from 16:00 to 17:10
- Venue: 17th Floor, Lupinus, Nagoya Marriott Associa Hotel
- Format: Poster Presentation (Free Discussion)
- Poster Number: P-23
- Title: Qualitative Improvement Effects of MSC-EV on Aging Mouse Embryos: A Promising Approach
- Lead Author: Izumi Kaneko, Head of Drug Discovery Research Department at EXORPHIA.

For further details, visit EXORPHIA’s website.

Commitment to Responsible Research and Development

In recent years, therapies utilizing EVs and stem cell culture supernatants have gained popularity for beauty and anti-aging purposes. However, concerns have been raised regarding their safety and efficacy due to insufficient validation. EXORPHIA sets itself apart by prioritizing quality, safety, and ethical considerations, and is dedicated to conducting responsible research and business development based on scientific evidence, while seeking advice from academic and professional experts.

Going forward, EXORPHIA aims to contribute to the advancement of healthcare across various fields through its research on extracellular vesicles. We encourage all attendees of the conference to visit our presentation and explore our groundbreaking findings.

Company Overview

- Company Name: EXORPHIA Co., Ltd.
- Location: Otemachi, Chiyoda-ku, Tokyo
- CEO: Koji Kuchiishi
- Established: 2019
- Business Focus: Development and sale of pharmaceuticals and additives (reagents) utilizing extracellular vesicles (EV).